[go: up one dir, main page]

WO2023037000A2 - Vaccin à arn comprenant un pool d'arn généré à partir d'un pool d'adn double brin - Google Patents

Vaccin à arn comprenant un pool d'arn généré à partir d'un pool d'adn double brin Download PDF

Info

Publication number
WO2023037000A2
WO2023037000A2 PCT/EP2022/075375 EP2022075375W WO2023037000A2 WO 2023037000 A2 WO2023037000 A2 WO 2023037000A2 EP 2022075375 W EP2022075375 W EP 2022075375W WO 2023037000 A2 WO2023037000 A2 WO 2023037000A2
Authority
WO
WIPO (PCT)
Prior art keywords
patient
sequence
peptide
tumor
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2022/075375
Other languages
English (en)
Other versions
WO2023037000A3 (fr
Inventor
Jean-Pol DETIFFE
Christophe Van Huffel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncodna
Original Assignee
Oncodna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21196366.5A external-priority patent/EP4148146A1/fr
Priority claimed from EP21196390.5A external-priority patent/EP4147712A1/fr
Priority claimed from EP21196406.9A external-priority patent/EP4147713A1/fr
Priority to EP22786889.0A priority Critical patent/EP4401761A2/fr
Priority to CN202280075564.4A priority patent/CN118251233A/zh
Priority to IL311298A priority patent/IL311298A/en
Priority to CA3230575A priority patent/CA3230575A1/fr
Application filed by Oncodna filed Critical Oncodna
Priority to JP2024516457A priority patent/JP2024531723A/ja
Priority to US18/691,296 priority patent/US20250215060A1/en
Publication of WO2023037000A2 publication Critical patent/WO2023037000A2/fr
Publication of WO2023037000A3 publication Critical patent/WO2023037000A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the present disclosure concerns the use of information extracted from the genome of a patient to generate a ribonucleic acid RNA vaccine.
  • the discovery of a process for producing a RNA vaccine comprising a plurality of epitopes specifically deduced from a target from an infectious agent or cancer neoepitopes.
  • the present disclosure refers to a mRNA cancer vaccine for a patient having a tumor.
  • the present invention also refers to an ex vivo method to select neoantigens to the patient comprising the step of submitting a blood sample from the patient having been administered with the mRNA cancer vaccine.
  • personalized vaccine e.g. personalized therapeutic vaccine comprising tumor-specific antigens (neoantigens) of the tumor of the patient, to treat the tumor hold great promise as a nextgeneration of personalized cancer immunotherapy.
  • the concept of personalized cancer vaccination is based on the identification of the neoantigens able to trigger the appropriate immunological response. This will allow to generate an optimal personalized vaccine, which will specifically boost the patient's immune system in attacking the tumor.
  • RNA vaccines were developed in personalized cancer therapy but also to threat and/or the prevent different infectious diseases.
  • the RNA vaccines may be used to induce a balanced immune response against cancers or against an infectious disease, comprising both cellular and humoral immunity, without risking the possibility of insertional mutagenesis, for example.
  • the RNA vaccines may be utilized to treat and/or prevent a disease or a cancer of various stages or degrees of metastasis.
  • RNA (mRNA) vaccine which is especially true for personalized mRNA cancer vaccine, is to properly identify the specific epitopes, i.e. tumor neoepitopes, that will elicit a proper immunological response in the patient leading to a sufficient activation of T cells in the patient to attack efficiently the tumor and/or the disease.
  • the document EP3400005 relates to an anticancer vaccine being directed to a plurality of neoepitopes from tumor neoantigens. Thereby, a personalized neoantigen vaccine is obtained that specifically targets the identified tumor antigens.
  • the present invention relates to a therapeutic anticancer vaccine comprising an immunologically effective amount of a polynucleotide comprising a nucleotide sequence encoding an antigenic unit comprising (i) from 2 to 50 antigenic subunits, each subunit comprising at least a part of a cancer neoepitope sequence and a linker, (ii) a final cancer neoepitope sequence.
  • the production of a mRNA vaccine is based on in vitro transcription of a DNA template.
  • the DNA template which can be a plasmid or can result from multiple ligation steps of a plurality of DNA fragments, generally encodes for concatemeric epitopes or neoepitopes.
  • document WO 2018/144082 describes an RNA cancer vaccine and the process for producing it.
  • this document describes a concatemer-based mRNA vaccine where multiple cancerous epitopes are present on a single mRNA.
  • the document W02020/097291 describes a method for treating a patient's cancer with an mRNA vaccine.
  • the vaccine nucleic acid shows maximum anti-cancer efficacy for a given length.
  • the document by Kreiter Sebastian et al. mentions the efficiency of antigen presentation by coupling antigens to MHC molecules, where the vector has a promoter, a poly-A tail, and 3 1 UTR sequences.
  • mRNA cancer vaccine only 4 to 20% of the neoepitopes encoded by the mRNA vaccine are able to activate a T cell response.
  • a tumor can be characterized by numerous, e.g. more than 100, different neoepitopes.
  • a critical challenge is thus to select the appropriate neoepitopes, or the epitopes of a specific disease, that will be incorporated into the mRNA vaccine to trigger a proper immunological response in the patient.
  • the present invention provides o process for producing o RNA vaccine comprising a plurality of epitopes specifically deduced from a target comprising the steps of:
  • the process according to the present invention permits to have a high number, potentially an unlimited number, of different DNA constructs.
  • the RNA vaccine according to the present invention can incorporate a very large number of epitopes of the infectious disease or of epitopes, i.e. neoepitopes, from a tumor and a number of them will lead to T cells activation of the patient.
  • the immunological response in the patient refers to the production of specific T cells, preferably cytotoxic T cells, targeting the neoantigen(s) or the infectious agent.
  • the immunological response is tested in vitro by measuring the production of one or more immunological markers, for example IFN- gamma, by T cells of the patient, wherein said T cells of the patient are put in contact with specific epitopes of the mRNA vaccine.
  • the immunological response is measured by the identification of CD8+ CD107a+ T cells from a blood sample of the patient having been administered with the mRNA vaccine of the present invention.
  • the term “at least one amino acid difference as compared with peptides from normal cells” means amino acid sequences encoded from open reading frames present in the DNA or the RNA of a tumoral cell from a patient, or DNA or RNA from an infectious agent, and not present in normal cells, i.e. in peripheral blood mononuclear cell (PBMC), of the patient, or a matched, non cancerous, tissue.
  • PBMC peripheral blood mononuclear cell
  • the present invention also relates to a mRNA cancer vaccine for a patient having a tumor comprising a plurality of mRNAs encoding a plurality of neoantigens, wherein said plurality of neoantigens is deduced from the tumor, wherein said plurality of mRNAs encodes for at least 1% of all tumor neoantigens identified in the tumor, preferably for at least 2%, more preferably at least 5%, even more preferably at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% of all tumor neoantigens identified in the tumor.
  • the present invention also refers to a ex vivo method to select neoantigens to a patient comprising the step of submitting a blood sample from a patient having been administered with the mRNA cancer vaccine according to the present invention or with the RNA vaccine obtainable by the process according to the present invention to the corresponding synthetic peptide neoepitopes, or to one or several truncated version thereof, and of identifying which synthetic peptide neoepitopes triggers an immune response.
  • the term “neoontigen” refers to a tumor-specific antigen of the patient.
  • a “neoantigen” comprises an amino acid sequence different, by at least one amino acid, as compared with peptides naturally present in normal cells of the patient.
  • the term “neoepitope” refers to a tumor-specific peptide originating from a neoantigen able to bind to major histocompatibility complex (MHC) of the patient.
  • MHC major histocompatibility complex
  • amino acid sequence different, by at least one amino acid, as compared with peptides naturally present in normal cells of the patient means (i) a peptide having an amino acid sequence having at least one amino acid different at a corresponding position of the amino acid sequence naturally present in normal cells of the patient, and/or (ii) a peptide that is not present in the normal cells of the patient, i.e. a de novo amino acid sequence present in the tumor and not present in normal cells of the patient (this situation shares more similarities with vaccination with an amino acid sequence of an infectious agent), and is thus advantageous.
  • amino acid sequence different, by at least one amino acid, as compared with peptides naturally present in normal cells of the patient covers neoantigens generated after translocation events or mutation in splicing sites; these events produce a peptide having a segment of high homology with a peptide from normal tissue and a C-terminal segment being different, or having a high homology with another peptide from a normal tissue.
  • any genetic event producing a peptide not 100% identical to a peptide found in a normal tissue corresponds to the above definition.
  • the DNA comprises a 3’ Poly A segment.
  • this 3' Poly A segment consists of 100% of adenosine, or consists essentially of adenosine; for instance stretches of at least 10 consecutive adenosine residues, preferably at least 20, 30, 40 consecutive adenosine residues, separated by other nucleotides (a stretch of less than 20, preferably less than 10 residues not forming the above stretch), and followed by a second stretch of at least 10 consecutive adenosine residues (independently of the length of the first stretch, at least 20, 30, 40 consecutive adenosine residues), possibly followed by separating nucleotides (less than 20, preferably less than 10 residues not forming a stretch) and subsequent adenosine stretches is also comprised by the terminology Toly A segment’, provided that at least
  • the inventors have developed a process for producing a mRNA vaccine comprising a plurality of epitopes specifically deduced from a target. This allows to ensure the administration of epitopes that will be recognized by the patient’s immune system.
  • the inventors have shown that such an approach provides a more robust immune response than a vaccination-based method where one, or a few, different epitope(s) have been administered to a patient, even if the epitopes are selected and/or designed using the state-of the art technology, including the bioinformatics tool developed to increase the predictability of an immune response.
  • Such a positive result is surprising in view of the dilution of the potent epitopes, by the large amount of the non-potent ones.
  • This process comprises the steps of :
  • the said target is a peptide from an infectious agent or cancer neoepitopes specifically identified in one patient and having an amino acid sequence different, by at least one amino acid, as compared with peptides naturally present in normal cells of the patient.
  • the transcription of the DNA into the RNA sequence is performed in the presence of pseudouridine and/or of Nl- Methylpseudouridine, 15-methyluridine (m5U), and/or 2-thiouridine (s2U).
  • pseudouridine and/or of Nl- Methylpseudouridine, 15-methyluridine (m5U), and/or 2-thiouridine (s2U).
  • the process to obtain the RNA sequence comprises a further step of adding a 5’ Cap element, comprising two nucleotides separated (linked in 5'-3') by a triphosphate stretch.
  • the two nucleotides can be natural, or modified, for instance by methylation of the -OH residue at the 2’ position (2-0-Me nucleotides) in one or in the two residues forming the 5’ Cap element.
  • the 5’ Cap element can comprise additional groups, including additional nucleotides, provided that two nucleotides are separated (linked in 5’ -3’ ) by a triphosphate group, instead of a monophosphate.
  • the DNA construct [hence the encoded mRNA as well) further comprises a plurality of sequences elements encoding a peptide sequence for endosomial targeting of the encoded peptide.
  • the peptide sequence for endosomial targeting is the signal sequence of a lysosome-associated membrane protein (LAMP] or LAMP2), for instance of dendritic cells (DC-LAMP) and/or a sequence targeting the epitope to the MHC-I receptor, such as SEQ ID NO:3.
  • LAMP lysosome-associated membrane protein
  • DC-LAMP dendritic cells
  • the DNA construct (hence the encoded mRNA as well) further comprises a plurality of sequences elements encoding a peptide sequence for the loading of the encoded peptide for presentation to T lymphocytes. More preferably, the plurality of sequence elements encoding a peptide sequence for the loading of the encoded peptide for presentation to T lymphocytes is a dendritic cell lysosomal associated membrane glycoprotein signal sequence, such as SEQ ID NO:5.
  • the plurality of the different DNA constructs share the same plurality of sequences elements encoding a peptide sequence forendosomial targeting of the encoded peptide and/or the same plurality of sequences elements encoding a peptide sequence for the loading of the encoded peptide for presentation to T lymphocytes.
  • the sequence allowing the translation of a RNA sequence into a peptide by an eukaryotic cell is a translation enhancer/promoter sequence located in a 5’UTR region (upstream of a coding region) of the DNA construct. More preferably, the sequence allowing the translation is a translation enhancer/promoter sequence chosen from the group of translation enhancer/promoter sequence comprising Human Cytomegalovirus (CMV) enhancer, alpha or betaglobin enhancer (such as SEQ ID NO:2), EF-1 alpha enhancer, simian virus 40 (SV40) enhancer, PGK1 promoter, Ubiquitin C promoter, HSD17B4 and beta-Actin promoter.
  • CMV Human Cytomegalovirus
  • alpha or betaglobin enhancer such as SEQ ID NO:2
  • EF-1 alpha enhancer such as SEQ ID NO:2
  • SV40 simian virus 40
  • the DNA construct [hence the encoded mRNA as well) further comprises at least one sequence element encoding 3'-UTR and/or a 3' Poly A tail segment(s). More preferably, the 3' Poly A tail segment(s) is of at least 68 nucleotides, favorably at least 100 nucleotides (see the definition here above).
  • the plurality of the DNA constructs shares the same promoter sequence (for the transcription in a RNA molecule).
  • the promoter sequence is a bacteriophage RNA polymerase promoter. More preferably, the promoter sequence belongs to a group of promoter sequences comprising a promoter sequence of T7 RNA polymerase (SEQ ID NO:1 ), of SP6 RNA polymerase, of T3 RNA polymerase, of Syn5 RNA polymerase, of KP34 RNA polymerase.
  • the promoter sequence according to the present invention is the promoter sequence of T7 RNA polymerase.
  • the transcription factor recognizing the shared promoter sequence is added during the transcription (transcribing) step.
  • the plurality of synthetic mRNA constructs in the pool is obtainable (obtained) by a process for the production of the plurality of synthetic DNA constructs comprising the steps of performing the synthesis of :
  • a first single stranded DNA molecule comprising a promoter for the transcription in RNA, a segment for its translation and a targeting sequence for endosomial addressing fused in-frame with a tumor neoantigen oran epitope from an infectious agent and a first portion of a genetic element encoding a sequence for the loading of the encoded tumor neoantigen or the epitope from an infectious agent for presentation to T lymphocytes, and
  • a second single stranded DNA molecule encoding a second portion of a genetic element encoding a sequence for the loading of the encoded tumor neoantigen or the epitope from an infectious agent for presentation to T lymphocytes, wherein the second single stranded DNA molecule is antisense and wherein the said first and second portions form the complete sequence for the loading of the tumor neoantigen or the epitope from an infectious agent for presentation to T lymphocytes and wherein the said first and second portions present an overlap (of at least 15 consecutive nucleotides) allowing a specific base pairing, the said process further comprising the step of hybridizing the DNA molecule under (i) with the DNA molecule under (ii) and of elongating the two molecules so as to generate a double stranded DNA molecule encoding a promoter a translational initiator, a targeting sequence for endosomial addressing fused in-frame with the tumor neoantigen or the epitope from an infectious agent and
  • the synthesis of the first single stranded DNA molecule and possibly of the second single stranded DNA molecule is (are) preferably synthesis using a silicon-based DNA writing technology.
  • the second single-stranded molecule is a ‘master stock’, that has been synthetized once, is enzymatically amplified, and stored, to increase the efficiency of the overall process, since only one molecule needs to undergo a chemical synthesis.
  • the process according to the present invention further comprises the preliminary step of optimizing the sequences of the plurality of DNA, preferably by selecting more abundant codons, and/or of avoiding detrimental secondary structures.
  • Detrimental secondary structures can be predicted using available in silica tools, thus, when possible, avoided.
  • pseudouridine is added during the transcription step into RNA.
  • pseudouridin is added, further to uridine or replacing all the uridine, during the transcription step into RNA.
  • pseudouridine and/or of Nl- Methylpseudouridine, 15- methyluridine (m5U), and/or 2-thiouridine (s2U) can be incorporated in the mRNA.
  • the RNA sequence of each mRNA of the plurality of mRNAs is enriched in pseudouridine, possibly by using codon degeneracy, while maintaining the sequence of the corresponding encoded peptide.
  • the RNA sequence comprises a 5’ Cap element, comprising two nucleotides separated (linked in 5'-3' ) by a triphosphate stretch.
  • the two nucleotides can be natural, or modified, for instance by methylation of the -OH residue at the 2' position (2-O-Me nucleotides).
  • the 5’Cop element con comprise additional groups, including additional nucleotides, provided that two nucleotides are separated (linked in 5'-3’) by a triphosphate group, instead of a monophosphate.
  • the plurality of different DNA molecules is of at least 40 different DNA molecules encoding at least 40 different epitopes, preferably at least 50, or at least 60, 80, 100 or even 120 different epitopes.
  • the process according to the present invention further comprises the step of amplifying the plurality of synthetic DNA constructs to generate an amplified pool of DNA constructs, wherein the amplified pool of DNA constructs is used as template for in vitro transcribing step.
  • the process for producing a mRNA vaccine further comprises, after the in vitro transcribing step, a step of checking the quality and/orthe quantity of each mRNA of the plurality of mRNAs.
  • the quality and/or the quantity of each mRNA of the plurality of mRNAs is performed by sequencing the plurality of mRNAs.
  • the process for producing a mRNA vaccine also further comprises a step of formulating the plurality of mRNAs, optionally with one or more adjuvants, into a vector administrable to a patient.
  • adjuvants are not required for such RNA vaccination, especially when uridine residues are less present, or totally replaced by pseudouridine.
  • the present invention also refers to a mRNA cancer vaccine for a patient having a tumor comprising a plurality of mRNAs encoding a plurality of neoantigens, wherein said plurality of neoantigens is deduced from the tumor, wherein said plurality of mRNAs encodes for at least 1% of all tumor neoantigens identified in the tumor, preferably for at least 2%, more preferably at least 5%, even more preferably at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% of all tumor neoantigens identified in the tumor.
  • the mRNA vaccine according to the present invention further comprises (i) a segment encoding a sequence for stabilizing and/or targeting and/or trafficking the tumor neoantigen, and/or (ii) a segment encoding a sequence for addressing the encoded tumor neoantigen to MHC molecules, and/or (iii) a segment encoding a translation enhancer, and/or (iv) a 3'-UTR and/or (v) a 3' Poly A tail segment(s) and/or (vi) a 5’-UTR.
  • the RNA sequences comprise a 5' Cap element, comprising two nucleotides separated (linked in 5’-3’) by a triphosphate stretch.
  • the two nucleotides can be natural, or modified, for instance by methylation of the -OH residue at the 2’ position (2-O-Me nucleotides).
  • the 5’Cap element can comprise additional groups, including additional nucleotides, provided that two nucleotides are separated (linked in 5'-3') by a triphosphate group, instead of a monophosphate.
  • the plurality of mRNAs encodes for at least 2%, preferably at least 5%, more preferably at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% of all tumor neoantigens identified in the tumor.
  • the plurality of mRNAs is incorporated in one or more lipid nanoparticles.
  • the plurality of mRNAs is complexed with positively-charged lipids.
  • the plurality of mRNAs and the positively-charged lipids are mixed in microfluidic chips.
  • one or more type 1 adjuvants is (are) incorporated with the plurality of mRNAs to form the mRNA cancer vaccine, wherein the one or more adjuvants is preferably selected from a group of adjuvants of type 1 having amorphous aluminum hydroxyphosphate sulfate (AAHS), aluminum hydroxide, aluminum phosphate, potassium aluminum sulfate (Alum), or Monophosphoryl lipid A.
  • AAHS amorphous aluminum hydroxyphosphate sulfate
  • Al hydroxide aluminum phosphate
  • Al phosphate aluminum phosphate
  • Alum potassium aluminum sulfate
  • Monophosphoryl lipid A Monophosphoryl lipid A
  • the plurality of mRNAs further comprises adjuvants of type 2 in the form of DNA or of mRNA such adjuvant of type 2 encoding for constitutively active TLR4 (caTLR4) and/or CD70 and/or CD40L and/or interferon-gamma and/or decoy interleukin receptors, i.e. Interleukin 1 receptor type II.
  • the adjuvant DNA or mRNAs of type 2 promotes the stimulation, when incorporated into the mRNA vaccine, of dendritic cells of the patient and increases the efficacy of presentation of the plurality of neoepitopes to T cells of the patient.
  • adjuvants are useful especially for the ex vivo maturation of dendritic cells of the patient.
  • the plurality of mRNAs further comprises adjuvants of type 3 in the form of DNA or of mRNA such adjuvant of type 3 encoding for a RNA-dependent RNA polymerase (RdRp), such as DNA or RNA encoding for the nonstructural proteins of the alphavirus nsPl -4.
  • RdRp RNA-dependent RNA polymerase
  • the plurality of mRNAs of the mRNA vaccine is able of transamplification, such as the trans-amplification based on the encoded RdRp.
  • trans-amplification permits to reduce the dose of mRNA vaccine administrated to the patient.
  • At least 25%, preferably at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or even 100% of uridine present in the RNA sequence of each mRNA of the plurality of mRNAs is replaced by pseudouridine or Nl - methylpseudouridine or 15-methyluridine or 2-thiouridine. More preferably, at least 25%, preferably at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or even 100% of uridine present in the RNA sequence of each mRNA of the plurality of mRNAs is replaced by pseudouridine.
  • the present invention also refers to ex vivo method to select neoantigens to a patient comprising the step of submitting a blood sample from a patient having been administered with the mRNA cancer vaccine according to the present invention or with the RNA vaccine obtainable by the process according to the present invention to the corresponding synthetic peptide neoepitopes, or to one or several truncated version thereof, and of identifying which synthetic peptide neoepitopes triggers an immune response.
  • this method to select neoantigens of a tumor of a patient comprising the step of submitting an ex vivo blood sample of this patient, having previously been given the plurality of the tumor neoantigens as described here above, and on testing against which neoepitopes does the said blood sample react.
  • This method allows to rapidly generate a more refined pool of neoantigens for treating this patient.
  • the peptides corresponding to the identified neoantigens are synthetized, then formulated in an aqueous solution in different compartments, and one peptide is allowed to react in a given compartment with the ex vivo sample.
  • truncated peptides can be generated having a sequence deduced from this neoantigen, for instance a peptide starting with the N-terminus extremity of the neoantigen, or with an amino acid downstream (e.g.
  • a second overlapping peptide is synthetized, where the first identified mutation is flanked by 3, 4, 5, 6, 7, 8, 9 amino acids upstream the first mutation and flanked by 3, 4, 5, 6, 7, 8, 9 amino acids downstream the first mutation.
  • a (second or third) overlapping peptide starting from the first identified mutation, or 1 , 2, 3, 4, 5 amino acids upstream this first identified mutation, and terminating at the C-terminal end of the neoantigen, or 1 , 2, 3, 4, 5 amino acids upstream of this C- terminal end of the neoantigen is synthetized as well.
  • These (two or three) overlapping peptides can be placed in the same compartment fortesting, or in two or three different compartments of the mRNA cancer vaccine according to the present invention or obtainable by the process according to the present invention for in vitro identification of a series of neoantigens of the tumor of the patient.
  • the present invention also refers to the neoantigens selected according to the ex vivo method of the present invention for use in vaccination of a patient affected by a tumor.
  • the present invention also refers to a method for expanding in vitro cytotoxic T cells specific against a tumor affecting a patient comprising the step of conditioning a blood sample from the said patient with the selected neoantigens of the present invention.
  • Example 1 Preparation of 97 mRNAs corresponding to neoepitopes identified in a lung tumor of a patient
  • the inventors have isolated the DNA and the RNA from a sample of a lung tumor of a patient.
  • the inventors also isolated the DNA from normal cells (peripheral blood mononuclear cells, PBMC) of the patient. Then, the following steps were performed:
  • identifying the DNA variants of the tumor encoding for neoantigens of the tumor by comparing the DNA sequenced data from the DNA of the tumorand the DNA from PBMC cells and by identifying the open reading frames of the tumor having a DNA variant leading to the detection of a mRNA transcript.
  • each neoepitope sequence is a part of the sequence of one neoantigen
  • Example 2 Composition of a mRNA vaccine according to the present invention
  • the inventors developed a mRNA vaccine comprising:
  • 97 different mRNAs encoding each a neoepitope of 27 amino acids identified from the lung tumor of the patient.
  • the total amount of these 97 different mRNAs is of 1000 g per dose of mRNA vaccine.
  • positively-charged lipids positively-charged lipids.
  • Example 3 Quality and quantity of the 97 different mRNAs included into the mRNA vaccine
  • the inventors Before incorporating the plurality of mRNAs (see 97 different mRNAs of the Example 1 ) into the mRNA vaccine composition (see Example 2), the inventors checked the quality and quantity of each mRNA of the plurality of mRNAs by performing an RNA sequencing. To do so, the inventors prepared double strand cDNA synthesis, using reverse transcriptase, and performed Illumina adapters ligation and cDNA library amplification by PCR. RNA Sequencing is then carried out in paired-end 100b mode with an high throughput equipment, here the Illumina NovaSeq 6000.
  • Example 4 Use of the mRNA vaccine as a diagnostic tool to produce a more efficient personalized mRNA vaccine by detection of T cells activation
  • the inventors used the mRNA vaccine of Example 2 as a diagnostic tool to identify amongst the 97 different mRNAs encoding each a different neoepitope, the neoepitopes that stimulate T cells of the patient.
  • the mRNA vaccine according to the Example 2 was administrated to the patient having a lung tumor. After 10 days, blood of the patient is collected, wherein peripheral blood mononuclear cells and T cells were isolated. T cells from PBMC of the blood were isolated by anti- CD3 magnetic beads (Milteny).
  • 3*97 peptides corresponding to the neoepitope amino acid sequences of the 97 different mRNAs were synthetized in an amount of 1 to 4 microgram of each peptide; in every case, one peptide starting from the N-terminal end of the neoantigen and finishing three amino acids after the first identified difference (mutation); the second peptide starting 7 amino acids before the first identified difference (mutation) and finishing 7 amino acids after it, and the third peptide starting 3 amino acids ahead of the first difference (mutation) and finishing at the C terminal end of the neoepitope.
  • Each peptide of the 3* 97 neoepitopes is tested by an ELISpot assay wherein T cells isolated from the blood of the patient are put in contact with each peptide (the three peptides derived from one neoepitope are present, combined, in one well). Then the inventors detect if T cells of the patient were activated by a given neoepitope (peptide) encoded by the mRNA vaccine by detecting the production of IFN-gamma in the well corresponding to the given neoepitope (peptide).
  • the inventors identified 63 neoantigens that activate T cells of the patient.
  • Example 5 Use of the mRNA vaccine as a tool to produce a second generation of mRNA vaccine by detection of CD8 cells activation
  • the mRNA vaccine according to the Example 2 was administrated to the patient having a lung tumor. After 10 days, a blood sample of the patient is collected, wherein peripheral blood mononuclear cells (PBMC) and T cells were isolated. T cells from PBMC of the blood were isolated by anti-CD3 magnetic beads (Milteny). From this isolated fraction of CD3+ cells (T cells), CD8+ and CD4+ cells were isolated by anti-CD8 and anti-CD4 magnetic beads, respectively. The fraction of CD3+ cells depleted from the CD8+ cells and CD4+ cells represents a fraction of antigen-presenting cells (APC).
  • PBMC peripheral blood mononuclear cells
  • T cells from PBMC of the blood were isolated by anti-CD3 magnetic beads (Milteny). From this isolated fraction of CD3+ cells (T cells), CD8+ and CD4+ cells were isolated by anti-CD8 and anti-CD4 magnetic beads, respectively.
  • the fraction of CD3+ cells depleted from the CD8+ cells and CD4+ cells
  • 3* 97 peptides corresponding to the neoepitope amino acid sequences of the 97 different mRNAs were synthetized using the same approach as in Example 4, in an amount of 1 to 4 microgram of each peptide.
  • Each peptide of the 97 neoantigens is tested by an ELISpot assay wherein T cells isolated from the blood of the patient is put in contact with each neoantigen (the three peptides derived from one neoantigen are present, combined, in one well). Then, the antigen-presenting cells (ARC) fraction is electroporated with each peptide in the presence of the CD8+ cells. Then the production of IFN- gamma has been measured.
  • ARC antigen-presenting cells
  • the inventors identified 24 neoantigens that activate specifically CD8+ cells of the patient.
  • Example 6 Use of the mRNA vaccine as a tool to produce a more efficient personalized mRNA vaccine by detection of CD107a.
  • CD 107a expression were measured in each well by using an anti-CD107a marker.
  • CD 107a is a marker of degranulation (indicator of functional cytotoxicity of CD8+ cells).
  • the cell therapy approach is preferred; hence the inventors have taken the advantage of the above wide and refined system to produce in vitro T cells able to directly attack the tumor.
  • cell therapy of the tumor were performed by isolating the 7 CD8+ CD107a+ cell lines of the patient.
  • DC cells of the patient have been maturated using the 7 optimized neoepitope administered as a mRNA vaccine, together with the administration by transfection of a plasmid encoding active TLR4 (caTLR4), CD70 and CD40L.
  • the 7 CD8+ CD 107a+ cell lines of the patient were expanded ex vivo before being reinjected into the patient having a lung tumor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

Un procédé de production d'un vaccin à ARN comprenant une pluralité d'épitopes déduits spécifiquement d'une cible comprend les étapes consistant à : obtenir une pluralité de constructions d'ADN synthétiques dans un pool (i) codant une pluralité d'épitopes différents déduits de ladite cible, et à transcrire in vitro ladite pluralité d'ADN synthétiques en une pluralité correspondante d'ARN, ladite cible étant un peptide provenant d'un agent infectieux ou de néo-épitopes cancéreux spécifiquement identifiés chez un patient et ayant une séquence d'acides aminés différente, d'au moins un acide aminé, par rapport aux séquences d'acides aminés naturellement présentes dans les cellules normales du patient.
PCT/EP2022/075375 2021-09-13 2022-09-13 Vaccin à arn comprenant un pool d'arn généré à partir d'un pool d'adn double brin Ceased WO2023037000A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US18/691,296 US20250215060A1 (en) 2021-09-13 2022-09-13 RNA Vaccine Comprising an RNA Pool Generated From a Double-Stranded DNA Pool
JP2024516457A JP2024531723A (ja) 2021-09-13 2022-09-13 二本鎖ｄｎａプールから生成されたｒｎａプールを含むｒｎａワクチン
EP22786889.0A EP4401761A2 (fr) 2021-09-13 2022-09-13 Vaccin à arn comprenant un pool d'arn généré à partir d'un pool d'adn double brin
CN202280075564.4A CN118251233A (zh) 2021-09-13 2022-09-13 一种包含由双链dna库产生的rna库的rna疫苗
IL311298A IL311298A (en) 2021-09-13 2022-09-13 An RNA vaccine containing a pool of RNA produced from a pool of double-stranded DNA
CA3230575A CA3230575A1 (fr) 2021-09-13 2022-09-13 Vaccin a arn comprenant un pool d'arn genere a partir d'un pool d'adn double brin

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP21196366.5A EP4148146A1 (fr) 2021-09-13 2021-09-13 Procédé pour générer des néo-antigènes personnalisés d'une tumeur d'un patient
EP21196406.9 2021-09-13
EP21196366.5 2021-09-13
EP21196390.5 2021-09-13
EP21196406.9A EP4147713A1 (fr) 2021-09-13 2021-09-13 Vaccin arn comprenant un groupe d'arn généré à partir d'un groupe d'adn à double brin
EP21196390.5A EP4147712A1 (fr) 2021-09-13 2021-09-13 Procédé pour générer un groupe d'adn à double brin codant pour des néo-antigènes d'une tumeur d'un patient

Publications (2)

Publication Number Publication Date
WO2023037000A2 true WO2023037000A2 (fr) 2023-03-16
WO2023037000A3 WO2023037000A3 (fr) 2023-04-20

Family

ID=83689350

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/EP2022/075375 Ceased WO2023037000A2 (fr) 2021-09-13 2022-09-13 Vaccin à arn comprenant un pool d'arn généré à partir d'un pool d'adn double brin
PCT/EP2022/075374 Ceased WO2023036999A1 (fr) 2021-09-13 2022-09-13 Procédé de génération d'un pool d'adn double brin codant pour des néo-antigènes d'une tumeur dun patient
PCT/EP2022/075371 Ceased WO2023036997A1 (fr) 2021-09-13 2022-09-13 Procédé de génération de néo-antigènes personnalisés d'une tumeur d'un patient

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/EP2022/075374 Ceased WO2023036999A1 (fr) 2021-09-13 2022-09-13 Procédé de génération d'un pool d'adn double brin codant pour des néo-antigènes d'une tumeur dun patient
PCT/EP2022/075371 Ceased WO2023036997A1 (fr) 2021-09-13 2022-09-13 Procédé de génération de néo-antigènes personnalisés d'une tumeur d'un patient

Country Status (6)

Country Link
US (3) US20250215060A1 (fr)
EP (3) EP4401760A1 (fr)
JP (3) JP2024531721A (fr)
CA (3) CA3230575A1 (fr)
IL (3) IL311298A (fr)
WO (3) WO2023037000A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144082A1 (fr) 2017-02-01 2018-08-09 Modernatx, Inc. Vaccins anticancéreux à arn
EP3400005A1 (fr) 2016-01-08 2018-11-14 Vaccibody AS Vaccin anticancéreux à arn de néoépitope
WO2020097291A1 (fr) 2018-11-07 2020-05-14 Modernatx, Inc. Vaccins à arn contre le cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2001516A4 (fr) * 2006-03-10 2010-04-28 Univ California Vaccins pour des virus provoquant des infections persistantes ou latentes
JP6656733B2 (ja) 2013-08-05 2020-03-04 ツイスト バイオサイエンス コーポレーション 新規合成した遺伝子ライブラリ
CA2975855C (fr) 2015-02-04 2025-09-23 Twist Bioscience Corp Compositions et methodes d'assemblage de gene synthetique
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
WO2018026920A1 (fr) 2016-08-03 2018-02-08 Twist Bioscience Corporation Surfaces texturées destinées à la synthèse de polynucléotides
WO2018183922A1 (fr) 2017-03-30 2018-10-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Procédés et compositions pour vacciner contre le paludisme
KR20200003390A (ko) * 2017-05-08 2020-01-09 그릿스톤 온콜로지, 인코포레이티드 알파바이러스 신생항원 벡터
EP3635594B1 (fr) 2017-06-09 2024-10-09 Gritstone bio, Inc. Identification, production et utilisation de néo-antigènes
US20200411135A1 (en) 2018-02-27 2020-12-31 Gritstone Oncology, Inc. Neoantigen Identification with Pan-Allele Models
AU2019293244A1 (en) 2018-06-27 2021-02-11 Modernatx, Inc. Personalized cancer vaccine epitope selection
WO2020139871A1 (fr) 2018-12-26 2020-07-02 Twist Bioscience Corporation Synthèse de novo polynucléotidique hautement précise
WO2021172990A1 (fr) 2020-02-28 2021-09-02 Frame Pharmaceuticals B.V. Néo-antigènes à cadre caché
WO2021185833A1 (fr) * 2020-03-16 2021-09-23 Vrije Universiteit Brussel Matrice d'adn synthétique pour transcription d'arnm in vitro

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3400005A1 (fr) 2016-01-08 2018-11-14 Vaccibody AS Vaccin anticancéreux à arn de néoépitope
WO2018144082A1 (fr) 2017-02-01 2018-08-09 Modernatx, Inc. Vaccins anticancéreux à arn
WO2020097291A1 (fr) 2018-11-07 2020-05-14 Modernatx, Inc. Vaccins à arn contre le cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KREITER SEBASTIAN ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 180, 2008, pages 309 - 318

Also Published As

Publication number Publication date
WO2023036999A1 (fr) 2023-03-16
JP2024533501A (ja) 2024-09-12
JP2024531721A (ja) 2024-08-29
US20250270736A1 (en) 2025-08-28
JP2024531723A (ja) 2024-08-29
CA3230575A1 (fr) 2023-03-16
WO2023036997A1 (fr) 2023-03-16
IL311298A (en) 2024-05-01
IL311304A (en) 2024-05-01
WO2023037000A3 (fr) 2023-04-20
EP4401760A1 (fr) 2024-07-24
US20250215060A1 (en) 2025-07-03
CA3230568A1 (fr) 2023-03-16
EP4401761A2 (fr) 2024-07-24
CA3230564A1 (fr) 2023-03-16
IL311302A (en) 2024-05-01
US20240379186A1 (en) 2024-11-14
EP4401762A1 (fr) 2024-07-24

Similar Documents

Publication Publication Date Title
JP5635058B2 (ja) 前立腺癌（Ｐｃａ）を治療するための組成物
EP2197481B1 (fr) Arn composition utilisée pour traiter le cancer bronchopulmonaire non à petites cellules (cbnpc)
TW202200199A (zh) 冠狀病毒疫苗及使用方法
KR20160042935A (ko) 폐암 치료를 위한 조성물 및 백신
EP4138854A2 (fr) Composés de coiffage, compositions et procédés d'utilisation associés
JP2025157393A (ja) Ｈｉｖ抗原及びｍｈｃ複合体
JP7762132B2 (ja) 新規な癌抗原及び方法
JP2025032114A (ja) 新規な癌抗原及び方法
US20250108105A1 (en) Self-amplifying rna compositions and methods of use thereof
JP2022540396A (ja) 新規な癌抗原及び方法
CN114341169A (zh) 新的癌抗原和方法
US20230167163A1 (en) Fusion proteins of ctl antigens for treating melanoma
WO2023037000A2 (fr) Vaccin à arn comprenant un pool d'arn généré à partir d'un pool d'adn double brin
US20230302109A1 (en) Antigen pool
EP4147713A1 (fr) Vaccin arn comprenant un groupe d'arn généré à partir d'un groupe d'adn à double brin
WO2025103803A1 (fr) Immunothérapie contre les tumeurs neuronales et cérébrales
WO2025224446A1 (fr) Nouveaux antigènes du cancer et procédés
WO2025133007A1 (fr) Nouveaux antigènes du cancer et procédés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22786889

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 3230575

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 311298

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2024516457

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022786889

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022786889

Country of ref document: EP

Effective date: 20240415

WWE Wipo information: entry into national phase

Ref document number: 202280075564.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 18691296

Country of ref document: US